Advertisement

Pneumo News

, Volume 11, Issue 2, pp 29–36 | Cite as

Inhomogene Tumorentität

Bei Thymustumoren steht die chirurgische Therapie noch im Vordergrund

  • Heidrun GroschEmail author
cme fortbildung
  • 37 Downloads

Zusammenfassung

Thymustumoren sind eine inhomogene Gruppe von Neoplasien unterschiedlicher Malignitätsgrade und prognostischer Perspektive. Die Operation ist der Goldstandard der Therapie. Im fortgeschrittenen Stadium ist eine interdisziplinäre Behandlung mit Beteiligung der Bereiche Chirurgie, Strahlentherapie und Onkologie nötig, angesichts der Seltenheit dieser Tumoren in Spezialzentren. Mit Vorsicht kann auch eine Immuntherapie indiziert sein.

Literatur

  1. 1.
    Engels EA. Epidemiology of Thymoma and Associated Malignancies J Thorac Oncol. 2010;5(10 Suppl 4):S260–5CrossRefGoogle Scholar
  2. 2.
    Marx A, Hohenberger P, Hoffmann H et al. The Autoimmune Regulator AIRE in Thymoma Biology Autoimmunity and Beyond. J Thorac Oncol. 2010;5(10 Suppl 4):S266–72CrossRefGoogle Scholar
  3. 3.
    Marx A, Chan JKC, Coindre JM et al. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. J Thorac Oncol. 2015;10(10):1383–95CrossRefGoogle Scholar
  4. 4.
    Detterbeck FC, Stratton K, Giroux D et al. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Propsal for an Evidence-Based Stage Classification System for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. J Thorac Oncol. 2014;9(9 Suppl 2):S65–72CrossRefGoogle Scholar
  5. 5.
    Koga K, Matsuno Y, Noguchi M et.al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int. 1994;44(5):359–67CrossRefGoogle Scholar
  6. 6.
    Refaeley Y, Simansky DA, Paley M et al. Resection and perfusion thermochemotherapy: A new approach for the treatment of thymic malignancies with pleural spread. Ann Thorac Surg. 2001;72(2):366–70CrossRefGoogle Scholar
  7. 7.
    Ried M, Potzger T, Braune N et al. Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumors: perioperative management and clinical experience. Eur J Cardiothorac Surg. 2013;43(4):801–7CrossRefGoogle Scholar
  8. 8.
    Girard N, Ruffini E, Marx A et al. Thymic epithelial tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v40–55CrossRefGoogle Scholar
  9. 9.
    Merveilleux du Vignaux C, Dansin E, Mhanna L et al. Systemic therapy in advanced thymic epithelial tumors: Insights from the RYTHMIC prospective cohort. J Thorac Oncol. 2018;13(11):1762–1770CrossRefGoogle Scholar
  10. 10.
    Thomas A, Rajan A, Berman A et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015;16(2):177–86CrossRefGoogle Scholar
  11. 11.
    Zucali PA, De Pas T, Palmieri G et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol. 2018;36(4):342–349CrossRefGoogle Scholar
  12. 12.
    Loehrer PJ, Wang W, Johnson DH et al. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma. J Clin Oncol. 2004;22(2):293–9CrossRefGoogle Scholar
  13. 13.
    Kirzinger L, Boy S, Marienhagen J et al. Octreotide LAR and prednisone as neoadjuvant treatment in patients with primary or locally recurrent unresectable thymic tumors: A phase II study. PLoS One. 2016;11(12):e0168215.  https://doi.org/10.1371/journal.pone.0168215CrossRefGoogle Scholar
  14. 14.
    Cho J, Kim HS, Ku BM et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: An open-label phase II trial. J Clin Oncol. 2018;  https://doi.org/10.1200/JCO.2017.77.3184
  15. 15.
    Giaccone G, Kim C, Thompson J et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018;19(3):347–355CrossRefGoogle Scholar
  16. 16.
    Rieker RJ, Muley T, Klein C et al. An Institutional Study on Thymomas and Thymic Carcinomas: Experience in 77 Patients. Thorac Cardiovasc Surg. 2008;56(3):143–7CrossRefGoogle Scholar
  17. 17.
    Grosch H, Hoffmann H, Weis CA, Thomas M. Thymustumoren. Onkologe. 2015;21(9):859–74CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Abteilung Internistische Onkologie der Thoraxtumoren ThoraxklinikUniversitätsklinikum HeidelbergHeidelbergDeutschland

Personalised recommendations